General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine
(2000; 80 pages) [French] [Spanish] Voir le document au format PDF
Table des matières
Afficher le documentAcknowledgements
Afficher le documentForeword
Ouvrir ce répertoire et afficher son contenuIntroduction
Ouvrir ce répertoire et afficher son contenu1. Methodologies for Research and Evaluation of Herbal Medicines
Ouvrir ce répertoire et afficher son contenu2. Methodologies for Research and Evaluation of Traditional Procedure-Based Therapies
Ouvrir ce répertoire et afficher son contenu3. Clinical Research
Ouvrir ce répertoire et afficher son contenu4. Other Issues and Considerations
Afficher le documentReferences
Ouvrir ce répertoire et afficher son contenuAnnexes
Ouvrir ce répertoire et afficher son contenuAnnex I. Guidelines for the Assessment of Herbal Medicinesa
Fermer ce répertoireAnnex II. Research Guidelines for Evaluating the Safety and Efficacy of Herbal Medicinesa
Afficher le documentDefinition of Terms
Afficher le documentGuidelines for Toxicity Investigation of Herbal Medicines
Afficher le documentAcute Toxicity Test
Afficher le documentLong-Term Toxicity Test
Ouvrir ce répertoire et afficher son contenuAnnex III. Report of a WHO Consultation on Traditional Medicine and AIDS: Clinical Evaluation of Traditional Medicines and Natural Productsa
Ouvrir ce répertoire et afficher son contenuAnnex IV. Definition of Levels of Evidence and Grading of Recommendationa
Ouvrir ce répertoire et afficher son contenuAnnex V. Guidelines for Levels and Kinds of Evidence to Support Claims for Therapeutic Goodsa
Ouvrir ce répertoire et afficher son contenuAnnex VI. Guidelines for Good Clinical Practice (GCP) for Trials on Pharmaceutical Productsa
Ouvrir ce répertoire et afficher son contenuAnnex VII. Guidance for Industry: Significant Scientific Agreement in the Review of Health Claims for Conventional Foods and Dietary Supplementsa
Ouvrir ce répertoire et afficher son contenuAnnex VIII. Guideline for Good Clinical Practicea
Ouvrir ce répertoire et afficher son contenuAnnex IX. WHO QOL (Quality of Life) User Manual: Facet Definitions and Response Scalesa
Afficher le documentAnnex X. Participants in the WHO Consultation on Methodologies for Research and Evaluation of Traditional Medicine
 

Acute Toxicity Test

Animal species

Some regulatory agencies require that at least two species be used, one of them to be selected from rodents and the other from non-rodents.

Sex

In at least one of the species, males and females should be used.

Number of animals

In the case of rodents, each group should consist of at least five animals per sex. In the case of non-rodents, each group should consist of at least two animals per sex.

Route of administration

Ordinarily, the oral route is sufficient as this is the normal route of clinical administration. However, some regulatory agencies suggest in addition a parenteral route of administration.

In cases where it is proposed to administer the herbal preparation to a human subject by the parenteral route, it may be sufficient to use this route alone for animal testing.

Dose levels

A sufficient number of dose levels should be used in rodents to determine the approximate lethal dose. In non-rodents, sufficient dose levels should be used for the observation of overt toxic signs.

Frequency of administration

The test substance should be administered in one or more doses during a 24-hour period.

Observation

Toxic signs and the severity, onset, progression and reversibility of the signs should be observed and recorded in relation to dose and time. As a general rule, the animals should be observed for at least seven to fourteen days.

Animals dying during the observation period, as well as rodents surviving to the end of the observation period should be autopsied.

If necessary, a histopathological examination should be conducted on any organ or tissue showing macroscopic changes at autopsy.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013